Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Average: 2014-2025

Historic Equity Average for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $228.8 million.

  • Theravance Biopharma's Equity Average rose 20.61% to $228.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.8 million, marking a year-over-year increase of 20.61%. This contributed to the annual value of $194.3 million for FY2024, which is 40.66% down from last year.
  • Latest data reveals that Theravance Biopharma reported Equity Average of $228.8 million as of Q3 2025, which was up 17.07% from $195.4 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Equity Average peaked at $461.2 million during Q4 2022, and registered a low of -$350.6 million during Q2 2022.
  • Its 3-year average for Equity Average is $236.2 million, with a median of $208.9 million in 2024.
  • In the last 5 years, Theravance Biopharma's Equity Average crashed by 86.97% in 2021 and then spiked by 302.46% in 2023.
  • Theravance Biopharma's Equity Average (Quarterly) stood at -$331.1 million in 2021, then surged by 239.30% to $461.2 million in 2022, then tumbled by 50.22% to $229.6 million in 2023, then decreased by 21.33% to $180.6 million in 2024, then increased by 20.61% to $228.8 million in 2025.
  • Its Equity Average stands at $228.8 million for Q3 2025, versus $195.4 million for Q2 2025 and $170.8 million for Q1 2025.